The Guardian “Global health disparities could ‘end in a generation’ with annual $60bn funding” DATE: December 2, 2013 LINK: http://www.theguardian.com/society/2013/dec/03/global-‐health-‐disparities-‐end-‐60bn-‐ funding The world's poorest nations would boost growth by almost a quarter and attain health standards and life expectancies comparable to those of wealthier mid-‐ranking countries if a concerted effort was made to invest in health systems, a landmark report concludes. Written by a group of 25 leading health experts and economists from across the globe and chaired by Larry Summers, a Harvard economist and former adviser to the Obama and Clinton administrations, the Lancet Commission report says "health disparities between nations could be eliminated within a generation" if around $60bn (£37bn) a year was injected into healthcare systems. In the year 2035 alone, roughly 10 million lives could be saved in low-‐income and middle-‐ income countries, "eliciting enormous social and economic gains for the countries most affected". The commission said the poorest nations in the world would see economic gains by bringing down mortality levels from maternal and childhood conditions, TB and Aids, to those achieved by the best-‐performing middle-‐income countries: Chile, China, Costa Rica, and Cuba, labelled the "4C" countries. In an interview Summers acknowledged that not enough progress had been made in global health – the rate of decline in maternal and child mortality in the developing world will not be sufficient to reach the United Nations' millennium development goals by 2015. However, he said that "any goal you are sure to meet is not a goal worth setting ... I think we have set an aspiration that is very much achievable". The "convergence plan" is summarised by the commission as "16-‐8-‐4" – reducing under-‐five mortality to 16 per 1,000 live births, cutting annual Aids deaths to eight per 100,000 population and bringing down annual tuberculosis (TB) deaths to four per 100,000 population. The commission warned that provision of public health goods would need to "regain prominence" for the strategy to succeed. In 1990, only $47bn was spent on health research worldwide. By 2009, annual funding had risen to $248bn, of which 60% came from the business sector and was mostly targeted at developed-‐world conditions such as cancer. Only about $3bn, representing just 1% of total spend, is spent annually on R&D for infectious diseases – of particular concern to low-‐income and middle-‐income countries. "Clearly resources should not just be driven by commercial priorities," Summers said, echoing the report's conclusion that research budgets in this area needed to double. Not only are the wrong diseases targeted but underfunding of global institutions remains a